The early detection research network's specimen reference sets: Paving the way for rapid evaluation of potential biomarkers

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 68-74

  Feng, Ziding ^a   Kagan, Jacob ^b   Pepe, Margaret ^a   Thornquist, Mark ^a   Rinaudo, Jo Ann ^b   Dahlgren, Jackie ^a   Krueger, Karl ^b   Zheng, Yingye ^a   Patriotis, Christos ^b   Huang, Ying ^a   Sorbara, Lynn ^b   Thompson, Ian ^c   Srivastava, Sudhir ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; THROMBOSPONDIN 1;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; EARLY DIAGNOSIS; FOLLOW UP; FREEZE THAWING; HUMAN; LIVER CANCER; LONG TERM CARE; PATIENT DECISION MAKING; PROSTATE CANCER; SHORT SURVEY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSLATIONAL RESEARCH; TUMOR BIOPSY;

EID: 84872038824     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.185140     Document Type: Short Survey

References (11)

1. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. (Pubitemid 34178440)
2. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8. (Pubitemid 35277282)
3. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14. (Pubitemid 34728833)
4. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003;19:185-95. (Pubitemid 38869698)
5. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12. (Pubitemid 40024018)
6. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53-60. (Pubitemid 351182596)
7. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008;54:44-52. (Pubitemid 351182595)
8. National Cancer Institute. Early Detection Research Network. http://edrn.nci.nih.gov/ (Accessed October 2012).
9. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, et al. [-2]prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study. J Urol 2008;180:539-43.
10. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200.
11. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter DJ. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.